Information Provided By:
Fly News Breaks for February 27, 2015
PCYC
Feb 27, 2015 | 07:59 EDT
After Bloomberg reported that Pharmacyclics is considering selling itself, Bloomberg thinks the company could conceivably be sold for the $17B-$18B suggested by press reports. However, the firm believes that whoever pays such a price would have "some heroic assumptions" about the outlook for Pharmacyclics' flagship drug, Inbruvica. Bernstein believes that if the company is not acquired, the stock will drop significantly from current levels, while it's unclear if the stock will rise much even if it is acquired. Bernstein keeps a Market Perform rating on the shares.
News For PCYC From the Last 2 Days
There are no results for your query PCYC
I agree to the thefly.com's disclaimer & terms of use
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.